scout

All News

SANTA MONICA, Calif-It can be especially difficult for physicians and managed care organizations to defend against patient lawsuits that include legal causes of action other than medical malpractice or negligence, said Michael Gonzalez, Esq, a defense attorney and partner in the Los Angeles firm of Kern, Streeter & Gonzalez.

NEW YORK-Two breast cancer survivors-one an oncologist from Albert Einstein College of Medicine, the other, the head of the National Alliance of Breast Cancer Organizations (NABCO)-were among those offering special perspectives at a public meeting on clinical and public policy issues related to breast cancer, sponsored by NABCO and held at Memorial Sloan-Kettering Cancer Center.

HAYWARD, Calif-Aradigm Corporation is working with SmithKline Beecham to develop a self-administered pulmonary drug delivery system to provide rapid pain relief. The new product is being developed for the treatment of cancer-related pain, especially breakthrough pain, as well as postoperative pain.

NEW ORLEANS-Although a good examination for oral cancer takes less than a minute to perform, most physicians do inadequate exams or fail to screen for oral cancer at all, according to the professor and head of oral pathology at Louisiana State University School of Medicine, New Orleans.

ORLANDO-Permanent trans-peritoneal ultrasound-guided radioactive implants (brachytherapy) get high marks for quality of life (QOL) in men with clinically localized prostate cancer, V. Elayne Arterbery, MD, reported in a poster session at the annual meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO).

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of

BETHESDA, Md-As life after a cancer diagnosis grows longer for more patients, how these survivors live with their disease grows more important. Now, the National Cancer Institute’s Office of Cancer Communications has issued The Cancer Journey: Issues for Survivors, a training program for all health care professionals, including nurses, doctors, social workers, and therapists, to help them understand issues cancer survivors face.

NEW ORLEANS-Improved treatment of cancer has not come without a price, including pulmonary complications directly related to radiation therapy, chemotherapy, and surgery. These were described in a symposium at the American College of Chest Physicians annual meeting.

CHICAGO-Hepatic artery infusion of fluorodeoxyuridine (floxuridine or FUDR) theoretically should benefit colorectal cancer patients with metastases in the liver because it delivers chemotherapy directly into the tumors. This not only raises intratumoral drug levels but also prolongs the duration of exposure of the tumors to chemotherapy without increasing toxicity.

NEW ORLEANS-There have been mountains of evidence from laboratory and epidemiologic studies about cancer prevention through nutrition, but only a “molehill” of intervention trials that will move the cancer prevention field forward, Dr. Daniel W. Nixon, president of the Society for Nutritional Oncology Adjuvant Therapy (NOAT), said at the 4th International Symposium on Nutrition and Cancer, jointly sponsored with the Cancer Treatment Research Foundation.

SANTA MONICA, Calif-The managed care system of delivering medical benefits has not only altered the way physicians provide care but also drastically changed the landscape in health care law, said Mark O. Hiepler, Esq, a plaintiff attorney and partner in the firm of Hiepler & Hiepler, Oxnard, California.

PHOENIX, Ariz-A woman with an indeterminate mammogram is often told to “wait and see what develops,” and to schedule another mammogram in 3 to 6 months. The radiodiagnostic test Miraluma (Kit for the Preparation of Technetium Tc99m Sestamibi) offers a noninvasive second step to women who might otherwise have to “wait and see,” Hirsch Handmaker, MD, said in an interview.

NEW ORLEANS-Heavy drinking can lead to cancer of the head, neck, esophagus, and liver, but whether moderate alcohol consumption increases risk at these sites is still unclear, said Matthew P. Longnecker, MD, of the National Institute of Environmental Health Sci-ences, Research Triangle Park, NC.

RESEARCH TRIANGLE PARK, North Carolina-Saccharin just missed winning a reprieve. By a 4-to-3 vote, an advisory panel recommended that the federal government continue to list the artificial sweetener as “reasonably anticipated to be a human carcinogen.”

TORONTO-Neutropenic cancer patients are often given quinolones in an attempt to ward off infection, but a recent metaanalysis suggests that little is gained from prophylaxis. Furthermore, development of quinolone resistance in such patients may deprive clinicians of an effective oral therapy that could be used as outpatient treatment in patients who do develop infections.

TORONTO-A worldwide, longitudinal surveillance program of antimicrobial resistance, known as Sentry, is showing alarming resistance rates at sites in the United States, Canada, South America, and Europe, and some interesting geographical differences.

WASHINGTON-In a 650-page report prepared collaboratively by the American Institute for Cancer Research and the World Cancer Research Fund, international cancer experts have established that approximately one-third of all cancers are preventable through dietary changes, combined with physical activity and maintenance of recommended body weight. Avoidance of tobacco and alcohol could prevent another one-third of all cancers.

BETHESDA, Md-Fifteen consumer advocates will form the first Director’s Consumer Liaison Group (DCLG) at the National Cancer Institute. Panel members, most of them cancer survivors, were selected from a pool of 136 candidates. They will serve 3-year terms on the new advisory board, which will hold its first meeting in December.

Aboulafia provides an extensive review of the occurrence of and treatments for bone marrow disorders that complicate HIV infection and AIDS. Understanding of the pathogenesis of these disorders is increasing, and the availability of recombinant colony-stimulating factors (CSFs) has, in many ways, facilitated the treatment of HIV-1 infection and its complications. Nonetheless, numerous critical questions remain regarding the optimal use of these expensive and powerful reagents.

Neuroblastoma is a clinically heterogeneous disease which can have a benign, localized behavior or a rapidly progressive, widely disseminated, lethal character. In recent years, knowledge of tumor biology-genetic changes and other biological markers-has allowed for reliable prediction of patient outcomes. These markers, when combined with clinical staging and histologic findings, determine the relative risk for a given patient and allow therapy to be tailored to that particular level of risk.

B-cell non-Hodgkin’s lymphomas (NHL) are an increasingly common cause of cancer morbidity and mortality. In 1996, approximately 52,700 new cases of NHL were diagnosed, representing a marked increase in incidence. Indeed, the incidence rose from 8.5 per 100,000 population in 1973 to 15.1 per 100,000 in 1992.[1] About 20% to 30% of these are NHLs of the indolent varieties.

The article, Promoting Smoking Cessation Among Cancer Patients, is an excellent complement to the clinical practice guideline on smoking cessation recently published by the Agency for Health Care Policy and Research (AHCPR).[1] The guideline presented considerable detail for clinicians on how to help smokers who are prepared to quit. For the approximately 80% of smokers who are not prepared, the guideline included only a few paragraphs. The approach of Prokhorov, Hudman, and Gritz, seasoned clinicians and scientists, can help clinicians become much more confident when counseling all smokers, including those in the precontemplation and contemplation stages.

Anemia is a common complication of HIV infection. Erythropoietin (Procrit, Epogen) can correct anemia. When given to patients with HIV infection, erythropoietin ameliorates anemia and improves quality of life. Given these three facts, one wonders why an effective drug such as erythropoietin is not used appropriately in patients with HIV infections.

Neuroblastoma is the most common solid extracranial tumor in children. Although the outcome of patients with localized disease has improved substantially, the prognosis for those with advanced disease is still poor, despite multimodality therapeutic efforts of increasing intensity over the last 20 years. Dr. Matthay provides an excellent overview review of the biology and treatment of this devastating but fascinating childhood malignancy.

WASHINGTON-President Clinton, with Mrs. Clinton joining him, highlighted a three-pronged effort to ensure that women over age 40 have information about and access to regular and high-quality mammograms. The Clintons spoke during one of the President’s regular Saturday morning radio broadcasts.